Navigation Links
MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
Date:12/11/2007

(54.1%), pyrexia (51.8%), leukopenia (48.2%), diarrhea (36.4%), fatigue (35.9%), injection site erythema (35.0%), constipation (33.6%), neutropenia (32.3%) and ecchymosis (30.5%). Other adverse reactions included dizziness (18.6%), chest pain (16.4%), febrile neutropenia (16.4%), myalgia (15.9%), injection site reaction (13.6%), aggravated fatigue (12.7%) and malaise (10.9%). The most common adverse reactions by IV route also included petechiae (45.8%), rigors (35.4%), weakness (35.4%) and hypokalemia (31.3%).

Because treatment with Vidaza is associated with neutropenia and thrombocytopenia, complete blood counts should be performed as needed to monitor response and toxicity, but at a minimum, prior to each dosing cycle. Because Vidaza is potentially hepatotoxic in patients with severe pre- existing hepatic impairment, caution is needed in patients with liver disease. In addition, Vidaza and its metabolites are substantially excreted by the kidneys and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function.

Vidaza may cause fetal harm. While receiving treatment with Vidaza, women of childbearing potential should avoid becoming pregnant, and men should avoid fathering a child. In addition, women treated with Vidaza should not nurse.

About Pharmion

Pharmion is a leading global oncology company uniquely focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

'/>"/>
SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014  The acceptance of two ... AAGL Global Congress demonstrates continued interest in the ... provide bowel control. One of the abstracts, presented by ... Division Chief of Urogynecology and Reconstructive Pelvic Surgery ... Award for Best Written Abstract on Urogynecology/Pelvic Floor ...
(Date:11/21/2014)... -- Oxis International, Inc. (OXIS) (OXI.PA) announced today the resignation ... J. Cataldo as Chief Executive Officer, and Steven ... Ken Eaton resigned his positions as Chief Executive ... International, Inc. to pursue new opportunities. Mr. ... of Oxis International, Inc. Mr. Cataldo will continue to serve ...
(Date:11/18/2014)... 18, 2014  NxStage ® Medical Inc. ... of innovative dialysis products , today announced ... dialyzer for the in-center, hemodialysis market.  Streamline Express ... designed to reduce the amount of labor required ... of touch point contamination sites.  The dialyzer enables ...
Breaking Medicine Technology:LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3NxStage Launches New Streamline Express Dialyzer With Pre-attached Blood Tubing Set 2
... with its Investor Day being held tomorrow in New York ... forward-looking earnings expectations for the fourth quarter of Fiscal Year ... for Fiscal Year 2013.  The Company reconfirmed ... and for all of Fiscal Year 2012, as issued in ...
... hospitals handed a resolute vote of confidence over ... enterprise clinical and financial system. Healthmark Regional Medical ... Kit Carson Memorial Hospital plan on leveraging the ... meeting the meaningful use requirements associated with the ...
Cached Medicine Technology:PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day 2PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day 3PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day 4Hospitals Across the Country Select Prognosis HIS Enterprise Clinical and Financial System 2Hospitals Across the Country Select Prognosis HIS Enterprise Clinical and Financial System 3
(Date:11/22/2014)... November 22, 2014 Setria® Glutathione ... (TGA) approved it for use “as a therapeutically ... listed within the Therapeutic Goods (Listing) Notice 2014 ... Kyowa Hakko’s Setria® Glutathione will be exclusivity distributed ... that sources and imports fine chemicals to Australian ...
(Date:11/22/2014)... 22, 2014 In order to provide better ... of cocktail party dresses. The business knows that a suitable ... occasions. , Now, the party dresses supplier’s high ... off. As the leading company in fashion industry, LunaDress understands ... for every customer. So it always raises the professional level ...
(Date:11/22/2014)... November 22, 2014 A petition seeking ... http://www.morcellatorlawsuit2015.com ) in minimally-invasive hysterectomies and fibroid removal ... the end of October, Bernstein Liebhard LLP reports. ... as of November 21st, 2014. That represents an increase ... had signed on to the campaign.* , The campaign ...
(Date:11/22/2014)... November 22, 2014 The topic of ... of block retaining walls. The article states that, “While they ... several necessary steps that go into creating this powerful look.” ... a retaining wall is choosing which kind of block matches ... , B&D Rockeries says, “The two main options are concrete ...
(Date:11/22/2014)... Hastings and Hastings, a discount accident ... providing clients with the option of leaving an online ... flexible, intuitive and easy to navigate website that has ... Google + allows clients to research the Hastings and ... informed decision when retaining an attorney. Those who have ...
Breaking Medicine News(10 mins):Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3
... Events, DUBLIN, Ohio, April 8, 2008 Cardinal Health,Inc. ... services that improve,the safety and productivity of health care, plans ... prior to the opening of trading,on the New York Stock ... call for May 1 at,8:30 a.m. EDT to discuss results ...
... impact on childhood anxieties changes during adolescence, study found , , ... drive common fears, and new study finds, but the impact ... almost 2,500 twins born in Sweden from 1985 to 1986. ... ages 8 to 9, ages 13 to 14, ages 16 ...
... new study finds no effect , , TUESDAY, April 8 ... prevent relapses in patients with Crohn,s disease, concluded two ... Journal of the American Medical Association . , ... Dr. Brian Feagan, professor of medicine and director of ...
... Women on the hormone more than doubled the risk for ... Women who took a common form of estrogen as ... risk for certain types of benign breast disease compared with ... condition -- benign proliferative breast disease -- is relatively common ...
... mushroom (Ganoderma lucidum; Lingzhi) and green tea have long held ... countries, for the general promotion of health and long life ... studies have confirmed that both enhance the bodys immune functions ... types of cancer. , Now a new study ...
... frequently used illicit drugs by women during their childbearing ... during pregnancy, either alone or in combination with other ... There is strong evidence that THC, the main psychoactive ... abuse results in intrauterine growth retardation and that infants ...
Cached Medicine News:Health News:Cardinal Health to Announce Third-Quarter Results on May 1 2Health News:Cardinal Health to Announce Third-Quarter Results on May 1 3Health News:Genes' Influence on Fears Changes Over Time 2Health News:Omega-3 Fatty Acids Won't Prevent Crohn's Relapse 2Health News:Omega-3 Fatty Acids Won't Prevent Crohn's Relapse 3Health News:Estrogen Supplements May Raise Odds of Benign Breast Disease 2Health News:Extracts from reishi mushroom and green tea shows synergistic effect to slow sarcoma 2Health News:Marijuana increases alcohol toxicity in young rats 2
... The Arx Ceramic ... innovative, biocompatible implants based ... technology that offers physicians ... to other synthetic and ...
CVC 9005 Hematocrit Calibration Verification Controls are materials used for verifying the calibration and linearity of hematocrit sensors in IRMA TRUpoint cartridges for systems using software versi...
... control material used for monitoring the performance of ... for specific use on Bayer analyzers that measure ... 270) and the AVOX Systems CO-Oximeters (4000 and ... the IRMA TRUpoint®. CC 527 is available in ...
RNA1c Control is an assayed quality control material used for monitoring the performance of Bayer DCA Analyzers that measure Hemoglobin A1c. It may be used on DCA 2000 and 2000+ analyzers....
Medicine Products: